MD3413892T2 - Derivați de tetrahidroizochinolină - Google Patents

Derivați de tetrahidroizochinolină

Info

Publication number
MD3413892T2
MD3413892T2 MDE20181214T MDE20181214T MD3413892T2 MD 3413892 T2 MD3413892 T2 MD 3413892T2 MD E20181214 T MDE20181214 T MD E20181214T MD E20181214 T MDE20181214 T MD E20181214T MD 3413892 T2 MD3413892 T2 MD 3413892T2
Authority
MD
Moldova
Prior art keywords
muscle
troponin
disorders
tetrahydroisoquinoline
modulating
Prior art date
Application number
MDE20181214T
Other languages
English (en)
Inventor
Ippei Sato
Takashi Kamikubo
Masanori Miura
Yuji Matsushima
Hiroaki Tanaka
Yasuhiro Shiina
Susumu Yamaki
Tomoyuki Saito
Hiroshi Kiyohara
Munemichi OHE
Kayoko Mihara
Bradley Paul Morgan
Fady Malik
Scott Emile Collibee
Luke Ashcraft
Pu-Ping Lu
Jeffrey Michael Warrington
Marc Garard
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of MD3413892T2 publication Critical patent/MD3413892T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Noi compuşi derivaţi de tetrahidroizochinolină sunt dezvăluiţi aici care pot fi utilizaţi ca ingredient activ pentru o compoziţie farmaceutică utilă pentru prevenirea sau tratarea unei boli sau afecţiuni care răspunde la modularea contractilităţii sarcomerului scheletic. Aceasta poate fi realizată de exemplu, prin modularea complexului de troponină al sarcomerului muşchiului scheletic rapid prin una sau mai multe dintre miozina scheletică rapidă, actină, tropomiozină, troponină C, troponină I, şi troponină T, şi fragmente şi izoforme ale acestora. Compuşii derivat de tetrahidroizochinolină pot fi astfel utilizaţi ca agent pentru prevenirea sau tratarea 1) tulburărilor neuromusculare, 2) tulburărilor muşchiului voluntar, 3) tulburărilor SNC în care slăbiciunea, atrofia şi oboseala musculare sunt simptome proeminente, 4) simptomelor musculare care iau naştere din tulburări sistemice, şi 5) disfuncţii ale planşeului pelvian şi muşchiului sfincter uretral/anal.
MDE20181214T 2016-02-12 2017-02-10 Derivați de tetrahidroizochinolină MD3413892T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
PCT/US2017/017295 WO2017139526A1 (en) 2016-02-12 2017-02-10 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
MD3413892T2 true MD3413892T2 (ro) 2022-06-30

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20181214T MD3413892T2 (ro) 2016-02-12 2017-02-10 Derivați de tetrahidroizochinolină

Country Status (31)

Country Link
US (5) US9914741B2 (ro)
EP (2) EP4032877A1 (ro)
JP (2) JP6832943B2 (ro)
KR (1) KR20180120701A (ro)
CN (2) CN113666938A (ro)
AR (1) AR107592A1 (ro)
AU (1) AU2017217663B2 (ro)
BR (1) BR112018016475A2 (ro)
CA (1) CA3012839A1 (ro)
CL (1) CL2018002287A1 (ro)
CO (1) CO2018007920A2 (ro)
DK (1) DK3413892T3 (ro)
ES (1) ES2913423T3 (ro)
HR (1) HRP20220655T1 (ro)
HU (1) HUE058820T2 (ro)
IL (1) IL261055B (ro)
LT (1) LT3413892T (ro)
MA (1) MA44018B1 (ro)
MD (1) MD3413892T2 (ro)
MX (1) MX2018009759A (ro)
NZ (1) NZ746311A (ro)
PH (1) PH12018501694A1 (ro)
PL (1) PL3413892T3 (ro)
PT (1) PT3413892T (ro)
RS (1) RS63240B1 (ro)
RU (1) RU2743424C2 (ro)
SG (1) SG11201806416XA (ro)
SI (1) SI3413892T1 (ro)
TW (2) TWI773118B (ro)
UA (1) UA124879C2 (ro)
WO (1) WO2017139526A1 (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI773118B (zh) * 2016-02-12 2022-08-01 美商細胞動力學股份有限公司 四氫異喹啉衍生物
CN116635378A (zh) 2020-11-06 2023-08-22 赛特凯恩蒂克公司 二环1,4-二氮杂环庚酮和其治疗用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (ro) 1971-09-16 1974-06-17 Kabi Ab
ATE232863T1 (de) 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
JP2001106673A (ja) 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
AU6314900A (en) 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
RS50756B (sr) 2004-04-28 2010-08-31 Takeda Pharmaceutical Company Limited Fuzionisani derivati hinolina i njegova upotreba
BRPI0620151A2 (pt) * 2005-12-22 2010-06-29 Wyeth Corp composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
ES2558517T3 (es) * 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
JP5197606B2 (ja) 2007-01-05 2013-05-15 第一三共株式会社 フューズ置換型アミノピロリジン誘導体
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
EP2265588B1 (en) * 2008-02-27 2013-06-26 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
MX2011004535A (es) 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
WO2010131147A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
CN108553467A (zh) 2012-04-02 2018-09-21 赛特凯恩蒂克公司 改善膈肌功能的方法
KR102163931B1 (ko) 2012-04-11 2020-10-12 싸이토키네틱스, 인코포레이티드 골격근 피로에 대한 저항을 개선
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
SI3137622T1 (sl) 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
ES2750751T3 (es) 2014-09-09 2020-03-27 Astellas Pharma Inc Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria
TWI773118B (zh) 2016-02-12 2022-08-01 美商細胞動力學股份有限公司 四氫異喹啉衍生物

Also Published As

Publication number Publication date
WO2017139526A1 (en) 2017-08-17
CN109069498B (zh) 2021-08-17
IL261055A (en) 2018-10-31
EP3413892B1 (en) 2022-04-20
BR112018016475A2 (pt) 2018-12-26
JP7137650B2 (ja) 2022-09-14
ES2913423T3 (es) 2022-06-02
TW202138373A (zh) 2021-10-16
US9914741B2 (en) 2018-03-13
MA44018A (fr) 2018-12-19
RU2018130002A (ru) 2020-03-12
JP2021073270A (ja) 2021-05-13
AR107592A1 (es) 2018-05-16
WO2017139526A8 (en) 2018-08-16
DK3413892T3 (da) 2022-05-23
AU2017217663A1 (en) 2018-10-04
IL261055B (en) 2021-03-25
RU2018130002A3 (ro) 2020-03-24
SG11201806416XA (en) 2018-08-30
CA3012839A1 (en) 2017-08-17
US20200270266A1 (en) 2020-08-27
HUE058820T2 (hu) 2022-09-28
MA44018B1 (fr) 2022-05-31
TWI773118B (zh) 2022-08-01
CN109069498A (zh) 2018-12-21
EP3413892A1 (en) 2018-12-19
EP3413892A4 (en) 2019-08-14
US11479561B2 (en) 2022-10-25
MX2018009759A (es) 2018-11-29
RU2743424C2 (ru) 2021-02-18
US10259821B2 (en) 2019-04-16
AU2017217663B2 (en) 2021-06-17
PH12018501694A1 (en) 2019-01-28
CL2018002287A1 (es) 2019-01-04
US20180148458A1 (en) 2018-05-31
TWI719138B (zh) 2021-02-21
US20190194220A1 (en) 2019-06-27
TW201741316A (zh) 2017-12-01
PT3413892T (pt) 2022-05-30
US10689393B2 (en) 2020-06-23
UA124879C2 (uk) 2021-12-08
JP2019509267A (ja) 2019-04-04
LT3413892T (lt) 2022-06-10
JP6832943B2 (ja) 2021-02-24
NZ746311A (en) 2022-08-26
EP4032877A1 (en) 2022-07-27
US20230125280A1 (en) 2023-04-27
US20170233402A1 (en) 2017-08-17
HRP20220655T1 (hr) 2022-06-24
CN113666938A (zh) 2021-11-19
PL3413892T3 (pl) 2022-06-13
CO2018007920A2 (es) 2018-12-14
KR20180120701A (ko) 2018-11-06
SI3413892T1 (sl) 2022-06-30
RS63240B1 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
MD3790877T2 (ro) Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
ATE524452T1 (de) Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen.
MX2021004431A (es) Procesos novedosos.
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20062703L (no) Maleatsalter av et kinazolinederivater anvenbare som antiangiogenisk middel
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
ATE489088T1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
MD3413892T2 (ro) Derivați de tetrahidroizochinolină
Wang et al. Cutaneous hypoesthesia following plate fixation in clavicle fractures
MD3265459T2 (ro) Compuși amidici în calitate de agoniști ai receptorilor 5-HT4
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
MX2021006867A (es) Glutarato de 3-(1,2,3,6-tetrahidropiridin-2-il)piridina o un solvato farmaceuticamente aceptable del mismo.
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
DE602006003224D1 (de) Substituierte heterocyclen, ihre verwendung als medikament und pharmazeutische zubereitungen, die sie enthalten
JOP20200012A1 (ar) تركيبة للاستخدام في الوقاية من مَرَضِيَّات جهاز القلبي الوعائي ومعالجتها
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten